Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorinostat + temozolomide
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vorinostat + temozolomide is a combination therapy consisting of the histone deacetylase (HDAC) inhibitor vorinostat and the DNA alkylating agent temozolomide. This combination was evaluated in a Phase 2 clinical trial (NCT01550224) led by Steven E. Coutre at Stanford University for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML). Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), works by inhibiting Class I and II HDAC enzymes, which leads to the hyperacetylation of histones and subsequent induction of cell cycle arrest and apoptosis. Temozolomide is an oral alkylating agent that induces DNA damage. The combination strategy aims to exploit potential epigenetic sensitization of leukemia cells to alkylating agents, with the trial stratifying patients based on MGMT promoter methylation status.
- Brand names
- ZolinzaTemodar
- Other names
- suberoylanilide hydroxamic acid
02
Targets
HDAC6 (Histone deacetylase 6)HDAC1 (Histone Deacetylase 1)
Beyond the preview
Go deeper on vorinostat + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorinostat + temozolomide.